Search results
Showing 691 to 705 of 734 results for adult social
Digital technologies to support self-management of COPD: early value assessment (HTG736)
Early value assessment (EVA) guidance on digital technologies to support self-management of COPD.
ERC1671 for treating progressed or recurrent grade IV glioma (glioblastoma or gliosarcoma) [ID1623]
In development Reference number: GID-TA10489 Expected publication date: TBC
Pexidartinib for treating symptomatic tenosynovial giant cell tumour [ID1682]
Discontinued Reference number: GID-TA10609
Discontinued Reference number: GID-TA10425
NICE has developed a medtech innovation briefing (MIB) on VAAFT for treating anal fistulae .
Evidence-based recommendations on raloxifene for the primary prevention of osteoporotic fragility fractures in postmenopausal women.
View recommendations for TA160Show all sections
Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases (TA412)
Evidence-based recommendations on radium-223 dichloride (Xofigo) for treating hormone-relapsed prostate cancer with bone metastases in adults.
Evidence-based recommendations on ceftazidime with avibactam for treating severe drug-resistant gram-negative bacterial infections.
View recommendations for AMR1Show all sections
Evidence-based recommendations on tezepelumab (Tezspire) for treating severe asthma in people 12 years and over.
Evidence-based recommendations on aflibercept (Zaltrap) with irinotecan and fluorouracil-based therapy (FOLFIRI) for treating metastatic colorectal cancer after oxaliplatin-based chemotherapy in adults.
Digital technologies to support smoking cessation in secondary care patients: early value assessment
In development Reference number: GID-HTE10061 Expected publication date: TBC
NICE has developed a medtech innovation briefing (MIB) on FLEXISEQ for osteoarthritis
Early value assessment (EVA) guidance on point-of-care tests for urinary tract infections to improve antimicrobial prescribing.
Evidence-based recommendations on ranibizumab (Lucentis) for treating diabetic macular oedema in adults.
View recommendations for TA274Show all sections
Evidence-based recommendations on alpelisib (Piqray) with fulvestrant for treating hormone receptor-positive, HER2-negative, PIK3CA-mutated, locally advanced or metastatic breast cancer in adults.